Rezolute FY26 net loss widens 4.26% to $77.59 million; G&A expenses climb 58.79% to $29.17 million
RZLT•Rezolute reported a fiscal 2026 net loss of $77.59 million, up from $74.41 million, as G&A expenses rose to $29.17 million. Cash, cash equivalents and marketable securities totaled $107.8 million at June 30, down from $167.9 million.
1. Fiscal 2026 results
Rezolute’s fiscal 2026 net loss widened to $77.59 million from $74.41 million a year earlier. Research and development expense fell 12.56% to $53.8 million, mainly because of lower ersodetug manufacturing costs, while general and administrative expense rose 58.8% to $29.17 million, linked to higher stock-based compensation and pre-commercial professional fees.
2. Cash and clinical studies
Cash, cash equivalents and marketable securities totaled $107.8 million at June 30, 2026, compared with $167.9 million a year earlier. Enrollment continues in the Phase 3 upLIFT tumor HI study, with topline results expected before the end of 2026; sunRIZE congenital HI data remain under FDA review.
